Islet Cell

A novel islet cell therapy delivered through a single infusion lowered HbA1c and eliminated severe hypoglycemia events for all adults with type 1 diabetes who received a full dose, according to data from a phase 1/2 study.

The FDA approved an allogenic pancreatic islet cellular therapy for adults with type 1 diabetes who struggled to achieve their target HbA1c due to repeated episodes of severe hypoglycemia, according to an agency press release.

Researchers at the American Diabetes Association Scientific Sessions reported that a patient with type 1 diabetes gained insulin independence after receiving an investigational stem cell-derived pancreatic islet cell therapy.

NEW ORLEANS — In this video exclusive, Richard E. Pratley, MD, offers his picks for most exciting news to come out of the American Diabetes Association Scientific Sessions.

NEW ORLEANS — A man with long-standing type 1 diabetes and no endogenous insulin production achieved insulin independence after an infusion of an investigational stem cell-derived pancreatic islet cell therapy, researchers reported.

For people living with type 1 diabetes and the clinicians and researchers who treat and study the disease, 2021 was a year of groundbreaking achievements and cause for optimism. Though as with any new experimental treatments, caveats abound.

The discovery of injectable insulin has saved countless lives over the past 100 years, but the next chapter in diabetes therapies — cell replacement therapy driven by stem cell islet products — represents a momentous turning point toward a disease-modifying cure.

On April 15, an FDA advisory committee concluded that the islet cell therapy donislecel demonstrated a favorable risk-benefit profile for certain patients with difficult-to-control type 1 diabetes.

Analyses from the ongoing TEDDY study suggest that islet autoimmunity develops by age 2 years for many children who go on to develop type 1 diabetes, and certain illnesses, gut microbiota and even diet may affect disease progression.